ЖИВОТНЫХ, УКАЗАННЫХ В [СТАТЬЕ 10](https://bukva.ai/docs/direktiva-201063es/statya-10#p100192)
1.
ВО [ВТОРОМ ПОДПАРАГРАФЕ СТАТЬИ 10 (1)](https://bukva.ai/docs/direktiva-201063es/statya-10#p100195)
| Виды | Сроки |
| --- | --- |
| Игрунка обыкновенная (Callithrix jacchus) | 1 января 2013 г. |
| Яванский макак (Macaca fascicularis) | 5 лет после публикации исследований технической осуществимости, указанных в [статье 10 (1), четвертый подпараграф](https://bukva.ai/docs/direktiva-201063es/statya-10#p100197), при условии, что в исследовании не рекомендуется больший срок |
| Макак-резус (Macaca mulatta) | 5 лет после публикации исследований технической осуществимости, указанных в [статье 10 (1), четвертый подпараграф](https://bukva.ai/docs/direktiva-201063es/statya-10#p100197), при условии, что в исследовании не рекомендуется больший срок |
| Другие виды нечеловекообразных приматов | 5 лет после публикации исследований технической осуществимости, указанных в [статье 10 (1), четвертый подпараграф](https://bukva.ai/docs/direktiva-201063es/statya-10#p100197), при условии, что в исследовании не рекомендуется больший срок |
ОБЛАСТЕЙ НАУЧНОГО ЗНАНИЯ, УКАЗАННЫХ В [СТАТЬЕ 23 (3)](https://bukva.ai/docs/direktiva-201063es/statya-23#p100291)
1.
СВЕДЕНИЙ, УКАЗАННЫХ В [СТАТЬЕ 37 (1) "c"](https://bukva.ai/docs/direktiva-201063es/statya-37#p100393)
1.
minimum floor area of 0,5 m and a minimum height of 40 cm. The duration of
the confinement shall be justified by the experimenter in consultation with
veterinary staff.
| Group size | Minimum enclosure size 2 (m ) | Minimum height (cm) | Minimum number of feeders | Date referred to in Article 33(2) |
| --- | --- | --- | --- | --- |
| Up to 6 | 1,0 | 100 | 2 | 1 January 2017 |
| 7 to 12 | 1,5 | 200 | 2 | |
| 13 to 20 | 2,0 | 200 | 3 | |
| for each additional bird above 20 | 0,05 | | 1 per 6 birds | |
#####
(c) non-invasive imaging of animals (e.g. MRI) with appropriate sedation or anaesthesia;
(d) superficial procedures, e.g. ear and tail biopsies, non-surgical subcutaneous implantation of mini-pumps and transponders;
(e) application of external telemetry devices that cause only minor impairment to the animals or minor interference with normal activity and behaviour;
(f) administration of substances by subcutaneous, intramuscular, intraperitoneal routes, gavage and intravenously via superficial blood vessels, where the substance has no more than mild impact on the animal, and the volumes are within appropriate limits for the size and species of the animal;
(g) induction of tumours, or spontaneous tumours, that cause no detectable clinical adverse effects (e.g. small, subcutaneous, non-invasive nodules);
(h) breeding of genetically altered animals, which is expected to result in a phenotype with mild effects;
(i) feeding of modified diets, that do not meet all of the animals' nutritional needs and are expected to cause mild clinical abnormality within the time-scale of the study;
(j) short-term (< 24h) restraint in metabolic cages;
(k) studies involving short-term deprivation of social partners, short-term solitary caging of adult rats or mice of sociable strains;
(l) models which expose animals to noxious stimuli which are briefly associated with mild pain, suffering or distress, and which the animals can successfully avoid;
(m) a combination or accumulation of the following examples may result in classification as "mild":
(i) assessing body composition by non-invasive measures and with minimal restraint;
(ii) monitoring ECG with non-invasive techniques with minimal or no restraint of habituated animals;
(iii) application of external telemetry devices that are expected to cause no impairment to socially adapted animals and do not interfere with normal activity and behaviour;
(iv) breeding genetically altered animals which are expected to have no clinically detectable adverse phenotype;
(v) adding inert markers in the diet to follow passage of digesta;
(vi) withdrawal of food for < 24h in adult rats;
(vii) open field testing.
2.
Moderate:
(a) frequent application of test substances which produce moderate clinical effects, and withdrawal of blood samples (> 10% of circulating volume) in a conscious animal within a few days without volume replacement;
(b) acute dose-range finding studies, chronic toxicity/carcinogenicity tests, with non-lethal end-points;
(c) surgery under general anaesthesia and appropriate analgesia, associated with post surgical pain, suffering or impairment of general condition. Examples include: thoracotomy, craniotomy, laparotomy, orchidectomy, lymphadenectomy, thyroidectomy, orthopaedic surgery with effective stabilisation and wound management, organ transplantation with effective management of rejection, surgical implantation of catheters, or biomedical devices (e.g. telemetry transmitters, minipumps etc.);
(d) models of induction of tumours, or spontaneous tumours, that are expected to cause moderate pain or distress or moderate interference with normal behaviour;
(e) irradiation or chemotherapy with a sublethal dose, or with an otherwise lethal dose but with reconstitution of the immune system. Adverse effects would be expected to be mild or moderate and would be short-lived (< 5 days);
(f) breeding of genetically altered animals which are expected to result in a phenotype with moderate effects;
(g) creation of genetically altered animals through surgical procedures;
(h) use of metabolic cages involving moderate restriction of movement over a prolonged period (up to 5 days);
(i) studies with modified diets that do not meet all of the animals' nutritional needs and are expected to cause moderate clinical abnormality within the time-scale of the study;
(j) withdrawal of food for 48 hours in adult rats;
(k) evoking escape and avoidance reactions where the animal is unable to escape or avoid the stimulus, and are expected to result in moderate distress.
3.
Severe:
(a) toxicity testing where death is the end-point, or fatalities are to be expected and severe pathophysiological states are induced. For example, single dose acute toxicity testing (see OECD testing guidelines);
(b) testing of device where failure may cause severe pain, distress or death of the animal (e.g. cardiac assist devices);
(c) vaccine potency testing characterised by persistent impairment of the animal's condition, progressive disease leading to death, associated with long-lasting moderate pain, distress or suffering;
(d) irradiation or chemotherapy with a lethal dose without reconstitution of the immune system, or reconstitution with production of graft versus host disease;
(e) models with induction of tumours, or with spontaneous tumours, that are expected to cause progressive lethal disease associated with long-lasting moderate pain, distress or suffering. For example tumours causing cachexia, invasive bone tumours, tumours resulting in metastatic spread, and tumours that are allowed to ulcerate;
(f) surgical and other interventions in animals under general anaesthesia which are expected to result in severe or persistent moderate postoperative pain, suffering or distress or severe and persistent impairment of the general condition of the animals. Production of unstable fractures, thoracotomy without adequate analgesia, or trauma to produce multiple organ failure;
(g) organ transplantation where organ rejection is likely to lead to severe distress or impairment of the general condition of the animals (e.g. xenotransplantation);
(h) breeding animals with genetic disorders that are expected to experience severe and persistent impairment of general condition, for example Huntington's disease, Muscular dystrophy, chronic relapsing neuritis models;
(i) use of metabolic cages involving severe restriction of movement over a prolonged period;
(j) inescapable electric shock (e.g. to produce learned helplessness);
(k) complete isolation for prolonged periods of social species e.g. dogs and non-human primates;
(l) immobilisation stress to induce gastric ulcers or cardiac failure in rats;
(m) forced swim or exercise tests with exhaustion as the end-point.